Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease

Neuroreport. 2002 Apr 16;13(5):601-4. doi: 10.1097/00001756-200204160-00013.

Abstract

The most frequently mutated gene resulting in dominantly inherited Alzheimer's disease is presenilin-1. We have used antibodies against advanced glycation endproducts (AGE) in brain tissue sections of four patients with three different presenilin I mutations. Accumulation of intracellular AGE was observed in 75-95% of pyramidal neurons in patients with presenilin-1 mutations, far exceeding the percentage of presenilin-1-, tau- or ubiquitin-positive neurons. This high level of AGE-modified proteins in vulnerable neurons is most likely explained by higher levels of their precursors (reactive (di)carbonyl products) or a slower turnover of the participating proteins. These conditions of carbonyl stress may contribute to increased neuronal dysfunction and vulnerability leading to the early disease onset.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Female
  • Glycation End Products, Advanced / genetics
  • Glycation End Products, Advanced / metabolism*
  • Humans
  • Interneurons / metabolism*
  • Interneurons / pathology
  • Male
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism*
  • Middle Aged
  • Mutation / genetics
  • Presenilin-1

Substances

  • Glycation End Products, Advanced
  • Membrane Proteins
  • PSEN1 protein, human
  • Presenilin-1